Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The…

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but…

‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon

Merck and Pfizer are the latest big pharma companies to invest in this booming area.

Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion

The deal expands the pharmaceutical company’s portfolio of cancer drugs.

Cancer Runs in Families. Too Few Are Getting Tested.

Doctors are recommending genetic tests to more cancer patients and their families. Costs have dropped, and…

New Treatment for Bladder Cancer Offers This Biotech a Second Chance

UroGen hopes to have success with a new treatment after its first drug was a commercial…

Drug Shortages Stem From Quality Problems in Indian Factories

Poor conditions at factories in India have sickened Americans and exacerbated chemotherapy-drug shortages for cancer patients,…

Some Cancer Patients Must Travel Hundreds of Miles for Medication

Health End of health emergency means independent cancer doctors can’t send prescriptions directly to their Medicare…

Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices

The drug maker filed suit, saying that Medicare’s drug-price negotiation program violates the company’s constitutional rights.